FDA Expands Approval for Sanofi's Tzield to Delay Type 1 Diabetes in Young Children

The U.S. Food and Drug Administration has broadened the use of Sanofi's drug Tzield, allowing it to be administered to children as young as one year old to delay the onset of type 1 diabetes.